C. Ola Landgren, MD, PhD, discusses the efficacy of idecabtagene vicleucel in the treatment of patients with relapsed/refractory myeloma.
C. Ola Landgren, MD, PhD, chief of Myeloma Service and hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses the efficacy of idecabtagene vicleucel (ide-cel; bb2121) in the treatment of patients with relapsed/refractory myeloma.
Efficacy findings with idecabtagene vicleucel were most recently presented at the 2020 ASCO Virtual Scientific Program, and previous data with the CAR T-cell product have been reported at several other meetings and published in the New England Journal of Medicine. The findings revealed that idecabtagene vicleucel leads to a clinical benefit in patients with relapsed/refractory multiple myeloma, Landgren says. Patients who experience a deep response with minimal residual disease negativity could have more than 1 year of clinical benefit following just a single infusion of this CAR T-cell therapy, concludes Landgren.